Ceryvyn Therapeutics Limited (ASX:CYV), formerly Opthea Limited, is rebuilding its clinical development program around CYV-101, a biologic being evaluated for lymphangioleiomyomatosis, or LAM.

The change follows the discontinuation of Opthea's wet age-related macular degeneration program after both Phase 3 trials of sozinibercept failed to meet their primary endpoints in March 2025. The company subsequently reduced its operating base, settled its Development Funding Agreement and redirected the same underlying molecule toward a different disease setting.

Wet-AMD Program Ends After Phase 3 Results

Opthea had been developing sozinibercept, previously known as OPT-302, as an add-on treatment for wet age-related macular degeneration.

The COAST Phase 3 study did not meet its primary endpoint in March 2025. The subsequent ShORe Phase 3 study also failed to meet its primary endpoint.

Following those results, the company discontinued development of sozinibercept in wet AMD and began reducing the operations built around the program.

Official filings state that the workforce was reduced by approximately 80% and the board was cut by more than half as the company closed clinical, Manufacturing and regulatory activities associated with the wet-AMD program.

Company Renamed Ceryvyn Therapeutics

The company later proposed changing its name from Opthea Limited to Ceryvyn Therapeutics Limited to reflect its revised development strategy.

Shareholders approved the change on 3 July 2026, and the ASX Code subsequently changed from OPT to CYV.

The new strategy centres on CYV-101, formerly OPT-302, for the treatment of lymphangioleiomyomatosis.

CYV-101 Targets VEGF-C and VEGF-D

CYV-101 is a fusion protein designed to bind VEGF-C and VEGF-D and prevent activation of VEGFR-3.

Ceryvyn is investigating this mechanism in LAM, a rare progressive disease that primarily affects the lungs of women.

LAM involves abnormal cell growth and changes in the lymphatic system. Ceryvyn's development rationale is based on the role of the VEGF-C and VEGF-D signalling pathway in lymphatic remodelling and disease progression.

The therapy remains investigational, and its effectiveness in LAM has not been established.

Development Moves to an Inhaled Approach

Ceryvyn's initial clinical strategy is focused on delivering CYV-101 directly to the lungs.

The company has been evaluating nebulised delivery as part of the LAM program and has undertaken preclinical feasibility work associated with inhaled administration.

This differs from the earlier ophthalmology program, where the molecule was administered into the eye.

The shift in delivery method and disease area means the LAM program requires separate clinical evaluation despite prior development work involving the same molecule.

Previous Clinical Exposure Provides Safety Data

CYV-101 was previously administered to a large number of patients during Opthea's ophthalmology development program.

Ceryvyn states that approximately 2,000 patients received the molecule during late-stage wet-AMD trials.

That prior exposure provides an existing body of safety and manufacturing information, but it does not demonstrate that the drug will be effective in LAM.

The new indication therefore remains subject to the normal requirements of clinical development, including evidence of safety, dosing and efficacy in the intended LAM patient population.

Balance Sheet Reshaped After Funding Settlement

The company's financial position changed materially following settlement of the Development Funding Agreement associated with the former wet-AMD program.

Under the settlement reached in August 2025, the funding investors received US$20 million in cash and shares representing 9.99% of the company's then fully diluted issued capital. The agreement removed the previous funding obligations connected with the wet-AMD program.

Ceryvyn subsequently reported an FY26 statutory profit of approximately A$330.4 million, compared with a loss in the previous year.

The headline profit largely reflected accounting effects associated with the restructuring and settlement rather than Revenue generated from commercial product sales.

Ceryvyn remains a clinical-stage biotechnology company without an approved commercial product.

Cash Position at June 2026

At 30 June 2026, Ceryvyn reported cash and cash equivalents of A$30.0 million.

Operating cash outflow for the June quarter was A$1.1 million, while Research and Development expenditure during the quarter was A$0.1 million.

These figures reflect the reduced operating structure following the closure of the wet-AMD program.

The company has not established recurring product revenue, meaning future clinical development remains dependent on its available capital and any additional funding arrangements required as the program progresses.

Single-Asset Development Concentrates Clinical Risk

Ceryvyn's current development strategy is centred primarily on CYV-101 and its potential application in LAM.

A concentrated pipeline means clinical progress in the LAM program has a greater influence on the company's development outlook than it would for a biotechnology company with several unrelated clinical assets.

The change of indication also introduces new questions around dose selection, inhaled delivery, clinical endpoints and regulatory requirements.

Earlier clinical use of the molecule in ophthalmology does not establish clinical benefit in LAM.

Next Development Steps

Ceryvyn is progressing the LAM development program while continuing regulatory and clinical planning.

Future disclosures are expected to provide additional information on trial design, dosing, regulatory engagement and development timelines.

The company has also established a scientific advisory board with pulmonary and LAM specialists to support the program.

The key evidence will come from clinical studies specifically evaluating CYV-101 in LAM rather than from the earlier ophthalmology trials.

Where Ceryvyn Stands

Ceryvyn has moved away from its former wet-AMD program and reduced its operating structure following the Phase 3 outcomes.

Its current strategy depends on whether CYV-101 can demonstrate clinical activity in LAM using a different route of administration and disease rationale.

The A$30.0 million cash balance reported at 30 June 2026 provides the financial starting point for that program, while subsequent cash-flow statements and clinical announcements will show how resources are being deployed as development advances.